Loading...
•
Apr 30, 2023
Cooper Q2 2023 Earnings Report
Revenue increased driven by CooperVision and CooperSurgical, but EPS decreased.
Key Takeaways
CooperCompanies reported a 6% increase in revenue to $877.4 million, with CooperVision and CooperSurgical showing growth. However, GAAP diluted EPS decreased by 69% to $0.80, while non-GAAP diluted EPS decreased by 5% to $3.08.
Revenue increased 6% year-over-year to $877.4 million.
CooperVision revenue was up 6% to $589.3 million.
CooperSurgical revenue was up 4% to $288.1 million.
GAAP diluted earnings per share (EPS) decreased 69% to $0.80.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Office & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
The Company updated its fiscal year 2023 financial guidance.
Positive Outlook
- Fiscal 2023 total revenue of $3,512 - $3,569 million (organic growth of 7% to 9%)
- CVI revenue of $2,365 - $2,400 million (organic growth of 8% to 10%)
- CSI revenue of $1,147 - $1,169 million (organic growth of 5% to 7%)
- Fiscal 2023 non-GAAP diluted earnings per share of $12.66 - $12.96
- Fiscal year 2023 guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income